AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 59 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $63,685 | -80.1% | 6,183 | -68.2% | 0.00% | -100.0% |
Q2 2023 | $319,976 | -69.1% | 19,416 | -82.8% | 0.00% | -75.0% |
Q1 2023 | $1,034,778 | +441.7% | 112,967 | +323.5% | 0.00% | – |
Q4 2022 | $191,007 | -55.2% | 26,677 | -57.3% | 0.00% | – |
Q1 2022 | $426,000 | -21.8% | 62,423 | -7.4% | 0.00% | – |
Q4 2021 | $545,000 | -16.9% | 67,447 | +0.8% | 0.00% | -100.0% |
Q3 2021 | $656,000 | +365.2% | 66,888 | +216.8% | 0.00% | – |
Q4 2020 | $141,000 | -39.7% | 21,113 | -54.5% | 0.00% | -100.0% |
Q3 2020 | $234,000 | +1200.0% | 46,443 | +635.9% | 0.00% | – |
Q2 2019 | $18,000 | +800.0% | 6,311 | +282.7% | 0.00% | – |
Q1 2019 | $2,000 | -92.6% | 1,649 | -84.1% | 0.00% | – |
Q4 2018 | $27,000 | -75.9% | 10,349 | -59.4% | 0.00% | -100.0% |
Q3 2018 | $112,000 | -8.9% | 25,482 | +27.1% | 0.00% | 0.0% |
Q2 2018 | $123,000 | -48.3% | 20,049 | -38.7% | 0.00% | -50.0% |
Q1 2018 | $238,000 | +235.2% | 32,715 | +280.0% | 0.00% | – |
Q4 2017 | $71,000 | – | 8,609 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 4,133,464 | $45,592,000 | 5.54% |
Stonepine Capital Management, LLC | 747,863 | $8,249,000 | 4.45% |
JW Asset Management, LLC | 444,439 | $4,902,000 | 3.12% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $40,320,000 | 2.15% |
ARMISTICE CAPITAL, LLC | 1,150,000 | $12,685,000 | 1.62% |
FALCON POINT CAPITAL, LLC | 855,101 | $9,432,000 | 1.27% |
Perceptive Advisors | 1,429,114 | $15,763,000 | 0.79% |
KNOTT DAVID M | 126,463 | $1,395,000 | 0.58% |
HEARTLAND ADVISORS INC | 700,000 | $7,721,000 | 0.50% |
Sio Capital Management, LLC | 91,413 | $1,008,000 | 0.48% |